Hydrocortisone News and Research

RSS

Tips to deal with insect stings

With the start of summer comes the appearance of common stinging insects, such as bees, wasps, hornets and yellowjackets, and the various related health risks that range from irritating but relatively harmless stings to the threat of serious allergic reaction. The National Pest Management Association (NPMA) stresses that when it comes to stinging insects, the best way to avoid the associated health risks is to practice simple prevention and treatment tips.

27 Jun 2012

Salix first quarter total product revenue increases 62% to $171.1M

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2012 and other business updates.

8 May 2012

GSK launches Medivir's Xerclear for OTC use in Europe

Medivir AB, the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore product Xerclear, which Medivir developed in-house, is now being launched for over-the-counter (OTC) use by its partner GlaxoSmithKline (GSK) in Europe.

8 Feb 2012

Oxygen Biotherapeutics to commence study to determine efficacy of Dermacyte in relieving Histamine induced pruritus

Oxygen Biotherapeutics, Inc. has announced that enrollment for the company’s first dermatological study will begin later this month at St. John’s Medical College Hospital in Bangalore, India. The company received formal approval from the hospital’s Ethics Review Board in December. This study is the first of a series of trials scheduled for 2012 to explore the efficacy of Dermacyte to treat a variety of dermatological conditions, such as allergic contact dermatitis, psoriasis and acne.

9 Jan 2012

CutisPharma introduces FIRST - Mouthwash Kits

CutisPharma, Inc. announced the introduction of FIRST - Mouthwash BLM 4oz and FIRST - Mouthwash BLM 6oz compounding kits. These products expand the FIRST Magic Mouthwash line for CutisPharma.

21 Dec 2011

Salix third quarter total product revenue increases 81% to $146.2 million

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the third quarter ended September 30, 2011 and other business updates.

9 Nov 2011

DuoCort Pharma granted marketing authorization for adrenal insufficiency drug, Plenadren in Europe

The Swedish specialty pharma company, DuoCort Pharma, announced today that the European Commission has granted a European Marketing Authorisation for Plenadren (hydrocortisone, modified release tablet), an orphan drug for treatment of adrenal insufficiency in adults, bringing these patients their first pharmaceutical innovation in over 50 years.

7 Nov 2011

WSU researcher to learn more about links between stress and drug use

A Wayne State University researcher is using a three-year, $1.55 million grant from the National Institute on Drug Abuse of the National Institutes of Health to learn more about the links between stress and drug use by applying behavioral economics.

27 Oct 2011

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for RELISTOR Subcutaneous Injection to treat opioid-induced constipation (OIC) in patients with non-cancer pain.

30 Aug 2011

Caffeine can treat postdural puncture headaches

People who suffer headaches after a spinal tap might have a relatively simple way to ease the painful throb: a caffeine tablet.

11 Aug 2011

Tips to minimize risk of bug bites and related illnesses

While the image of a bug crawling on your arm or a creepy crawler snuggling up in your bed is enough to make you flinch, most bug bites are harmless and disappear on their own in a matter of days. Other insects, however, can spread disease and cause severe reactions that require medical attention.

4 Aug 2011

Tips to make family vacations less hazardous for kids and parents

Family vacations live in infamy. Sometimes it's for the lasting memories of family bonding and new wonders experienced together, and sometimes for the horrors of just trying to get to a destination.

29 Jul 2011

Valeant to acquire rights relating to Elidel and Xerese from Meda

Valeant Pharmaceuticals International, Inc. announced today that its subsidiary, Valeant International SRL (VIB), has signed an agreement to acquire rights to both Elidel and Xerese from Meda, an international specialty pharmaceutical company for the U.S., Canada and Mexico.

30 Jun 2011

Valeant, Meda partner for life cycle opportunities for Elidel and Xerese

Meda and Valeant have entered into a collaboration agreement. Meda has out-licensed exclusive rights for Elidel and Xerese to Valeant for the U.S., Canada and Mexico. The parties will collaborate on life cycle opportunities for both products.

30 Jun 2011

Medivir, Meda renegotiate agreement for cold sores medicine, Xerese

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced that it has renegotiated the terms of its commercial partnership with Meda for Xerese, its unique marketed product for cold sores (herpes labialis).

29 Jun 2011

Daewoong, Medivir sign distribution agreement for Xerclear in China and Hong Kong

Medivir AB, a research-based specialty pharmaceutical company focused on infectious diseases, today announced that it has signed an agreement with Daewoong Pharmaceutical Co. Ltd. to exclusively distribute Medivir's unique cold sore treatment Xerclear in China and Hong Kong.

23 Jun 2011

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

Salix Pharmaceuticals, Ltd. today announced findings from two analyses of a Phase 3 open-label study of RELISTOR (methylnaltrexone bromide) presented at the 30th Annual Scientific Meeting of the American Pain Society. The meeting is being held in Austin, TX, on May 19-21, 2011.

21 May 2011